RA Capital Management’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

RA Capital Management’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,850,000	Closed	-$3.76M	–	109
2022 Q1	$3.76M	Hold	2,850,000	–	–	0.08%	90
2021 Q4	$7.44M	Hold	2,850,000	–	–	0.13%	87
2021 Q3	$8.86M	Hold	2,850,000	–	–	0.12%	81
2021 Q2	$10.6M	Hold	2,850,000	–	–	0.17%	72
2021 Q1	$9.86M	Buy	+2,850,000	New	+$11.6M	0.15%	72

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

RA Capital Management's PHAS Position: Q2 2022 in Review

RA Capital Management sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q2 2022, closing a stake of 2,850,000 shares — an estimated $3.76M sold.

RA Capital Management first reported a position in PHAS in Q1 2021 and held it in 5 quarters. The position peaked at $10.6M in Q2 2021. 49 funds tracked by Wall St. Rank hold PHAS as of Q2 2022.

RA Capital Management reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
RA Capital Management sold 2,850,000 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $3.76M.
RA Capital Management first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
RA Capital Management's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $10.6M in Q2 2021.
49 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on RA Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.